| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5316208
Max Phase: Preclinical
Molecular Formula: C20H29NO
Molecular Weight: 299.46
This compound is available for customization.
Associated Items:
ID: ALA5316208
Max Phase: Preclinical
Molecular Formula: C20H29NO
Molecular Weight: 299.46
Associated Items:
Canonical SMILES: C=CCCCCN1CC[C@]2(C)c3cc(O)ccc3C[C@@H]1[C@@H]2C
Standard InChI: InChI=1S/C20H29NO/c1-4-5-6-7-11-21-12-10-20(3)15(2)19(21)13-16-8-9-17(22)14-18(16)20/h4,8-9,14-15,19,22H,1,5-7,10-13H2,2-3H3/t15-,19+,20-/m0/s1
Standard InChI Key: MAYXDSGSHFBWRT-BEVDRBHNSA-N
Molfile:
RDKit 2D
23 25 0 0 0 0 0 0 0 0999 V2000
-3.0750 -0.0697 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.4205 -0.5720 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.6583 -0.2563 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.5506 0.5617 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.2051 1.0639 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.9673 0.7482 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.1561 -0.9108 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3381 -1.0185 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3568 0.0925 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.8961 1.0639 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3164 -0.5162 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.1096 1.8608 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.0782 0.9562 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.4241 0.3017 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.6218 1.2504 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
0.6614 0.8737 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.0309 -0.9287 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7453 -0.5162 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.4598 -0.9287 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.1743 -0.5162 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.8887 -0.9287 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.6032 -0.5162 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.1246 -1.8153 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 1 0
4 3 2 0
5 4 1 0
1 6 1 0
6 5 2 0
3 7 1 0
8 7 1 0
9 8 1 0
10 9 1 0
4 10 1 0
8 11 1 0
10 12 1 6
10 13 1 0
13 14 1 0
11 14 1 0
6 15 1 0
9 16 1 1
11 17 1 0
17 18 1 0
18 19 1 0
19 20 1 0
20 21 1 0
21 22 2 0
8 23 1 1
M END| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Molecular Weight: 299.46 | Molecular Weight (Monoisotopic): 299.2249 | AlogP: 4.27 | #Rotatable Bonds: 5 |
| Polar Surface Area: 23.47 | Molecular Species: BASE | HBA: 2 | HBD: 1 |
| #RO5 Violations: ┄ | HBA (Lipinski): 2 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): ┄ |
| CX Acidic pKa: 9.93 | CX Basic pKa: 10.78 | CX LogP: 4.05 | CX LogD: 1.94 |
| Aromatic Rings: 1 | Heavy Atoms: 22 | QED Weighted: 0.65 | Np Likeness Score: 1.56 |
| 1. Turnaturi R, Montenegro L, Marrazzo A, Parenti R, Pasquinucci L, Parenti C.. (2018) Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review., 155 [PMID:29908442] [10.1016/j.ejmech.2018.06.017] |
| 2. Hu, L Y LY and 5 more authors. 1997-12-19 Synthesis and pharmacological evaluation of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methylguanidines as N-methyl-D-aspartate receptor ion-channel blockers. [PMID:9435897] |
| 3. Husbands, S M SM and 6 more authors. 1997-12-19 Isothiocyanate derivatives of 9-[3-(cis-3,5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole): irreversible ligands for the dopamine transporter. [PMID:9435903] |
| 4. Ganapathy, M E ME and 5 more authors. 1999-04 Molecular and ligand-binding characterization of the sigma-receptor in the Jurkat human T lymphocyte cell line. [PMID:10087012] |
| 5. Cao, Jianjing J and 8 more authors. 2003-06-19 Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents. [PMID:12801223] |
| 6. Becker, Oren M OM and 12 more authors. 2006-06-01 An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. [PMID:16722631] |
| 7. Hajipour, Abdol R AR, Fontanilla, Dominique D, Chu, Uyen B UB, Arbabian, Marty M and Ruoho, Arnold E AE. 2010-06-15 Synthesis and characterization of N,N-dialkyl and N-alkyl-N-aralkyl fenpropimorph-derived compounds as high affinity ligands for sigma receptors. [PMID:20493718] |
| 8. Mésangeau, Christophe and 7 more authors. 2011-10 Synthesis and pharmacological evaluation of indole-based sigma receptor ligands. [PMID:21899931] |
| 9. Tu, Zhude and 6 more authors. 2012-07-15 Synthesis and evaluation of in vitro bioactivity for vesicular acetylcholine transporter inhibitors containing two carbonyl groups. [PMID:22739089] |
| 10. Riganas, Stefanos S and 17 more authors. 2012-11-26 New adamantane phenylalkylamines with σ-receptor binding affinity and anticancer activity, associated with putative antagonism of neuropathic pain. [PMID:23094992] |
| 11. Germain, Andrew R AR and 14 more authors. 2013-03-15 Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells. [PMID:23403082] |
| 12. Mach, Robert H; Zeng, Chenbo and Hawkins, William G. 2013-09-26 The σ2 receptor: a novel protein for the imaging and treatment of cancer. [PMID:23734634] |
| 13. Majo, Vattoly J and 8 more authors. 2013-09-01 Synthesis and in vivo evaluation of [(18)F]2-(4-(4-(2-(2-fluoroethoxy)phenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)-dione ([(18)F]FECUMI-101) as an imaging probe for 5-HT1A receptor agonist in nonhuman primates. [PMID:23816046] |
| 14. Di Fabio, Romano R and 15 more authors. 2013-11-01 Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate. [PMID:24075145] |
| 15. Peddibhotla, Satyamaheshwar S and 27 more authors. 2013-07-20 Discovery of ML314, a Brain Penetrant Non-Peptidic β-Arrestin Biased Agonist of the Neurotensin NTR1 Receptor. [PMID:24611085] |
| 16. Sampson, Dinithia and 9 more authors. 2014-06-15 Identification of a new selective dopamine D4 receptor ligand. [PMID:24800940] |
| 17. Bai, Suping and 8 more authors. 2014-05-22 Synthesis and structure-activity relationship studies of conformationally flexible tetrahydroisoquinolinyl triazole carboxamide and triazole substituted benzamide analogues as σ2 receptor ligands. [PMID:24821398] |
| 18. Mukherjee, Paramita and 7 more authors. 2015-02-12 Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase. [PMID:25489882] |
| 19. Gadhiya, Satishkumar and 7 more authors. 2016-05-01 Tetrahydroprotoberberine alkaloids with dopamine and σ receptor affinity. [PMID:27032890] |
| 20. Rui, Marta M and 15 more authors. 2016-11-29 Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-benzylpiperidines, novel Sigma Receptor (SR) modulators, as potential anticancer-agents. [PMID:27614411] |
| 21. Salvino, Joseph M JM and 5 more authors. 2017-05-15 Novel small molecule guanidine Sigma1 inhibitors for advanced prostate cancer. [PMID:28385503] |
| 22. Bautista-Aguilera, Óscar M ÓM and 9 more authors. 2018-08-09 Contilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile. [PMID:29969030] |
| 23. Tosh, Dilip K and 16 more authors. 2019-02-14 Design and in Vivo Characterization of A1 Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series. [PMID:30605331] |
| 24. García, Mónica and 11 more authors. 2020-03-12 4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ1 Receptor Antagonists for the Treatment of Pain. [PMID:31743642] |
| 25. Franchini, Silvia and 8 more authors. 2020-05-14 Novel Dithiolane-Based Ligands Combining Sigma and NMDA Receptor Interactions as Potential Neuroprotective Agents. [PMID:32435421] |
| 26. Jung, Young-Hwan and 13 more authors. 2020-09-10 Exploration of Alternative Scaffolds for P2Y14 Receptor Antagonists Containing a Biaryl Core. [PMID:32787142] |
Source(1):